Intravenous vitamin C megadose: the Marik protocol collapse and what replaced it

← Back to articles

For roughly three years after 2017, intravenous vitamin C at 1.5 g every six hours, combined with the steroid hydrocortisone and thiamine (vitamin B1)—the "HAT" or Marik protocol—was promoted as a breakthrough add-on treatment for sepsis, the body's life-threatening overreaction to infection. A single study that simply compared patients before and after the change reported that it nearly eliminated sepsis deaths. Every properly controlled trial that followed failed to reproduce that result, the largest one hinted at net harm, and combined analyses show no survival benefit. It is a textbook example of why one uncontrolled, single-hospital report cannot stand in for properly randomized evidence.

The 2017 case series that started it

Marik and colleagues published a retrospective before-after study at one hospital comparing 47 consecutive sepsis and septic-shock patients treated with HAT against 47 historical controls. Hospital mortality was 8.5% (4 of 47) in the treatment group versus 40.4% (19 of 47) in controls (P < 0.001), with a propensity-adjusted odds ratio for death of 0.13 (95% CI 0.04–0.48) [1]. The result spread rapidly into ICU order sets and critical-care social media as the "Marik cocktail" before any trial existed—though the authors themselves wrote that randomized confirmation was required.

The randomized trials that followed

Four randomized trials dismantled the claim. VITAMINS (216 patients with septic shock) found no difference in time alive and vasopressor-free to day 7 with HAT versus hydrocortisone alone (median 122.1 vs 124.6 hours; P = 0.83), and no difference in 90-day mortality [2]. CITRIS-ALI (167 patients with sepsis and ARDS) found no improvement in organ-failure scores or in inflammation and vascular-injury biomarkers despite a 96-hour vitamin C infusion [3]. ACTS (205 patients with septic shock) found no reduction in SOFA score at 72 hours and no mortality benefit (30-day mortality 34.7% vs 29.3%; hazard ratio 1.3, 95% CI 0.8–2.2) [4]. Most consequentially, the LOVIT trial (872 adults with sepsis on vasopressors), published in the New England Journal of Medicine in 2022, randomized patients to intravenous vitamin C 50 mg/kg every six hours or placebo and found a significantly higher risk of the composite of death or persistent organ dysfunction at 28 days in the vitamin C group (relative risk 1.21, 95% CI 1.04–1.40)—a signal of harm, not benefit [5].

What the pooled evidence shows

Meta-analyses confirm the absence of benefit. A 2023 systematic review of 24 randomized trials found that intravenous vitamin C did not significantly reduce short-term mortality (RR 0.82, 95% CI 0.65–1.02) or overall mortality (RR 0.86, 95% CI 0.74–1.01) in sepsis, with moderate-quality evidence [6]. A separate 2023 meta-analysis of 8 trials (1,394 patients) reached a similar conclusion, finding no benefit in septic shock specifically and, at most, a marginal and inconsistent signal in less severe sepsis [7]. There is no high-quality evidence that the HAT combination improves survival, and international sepsis guidance now recommends against routine intravenous vitamin C for sepsis. The protocol has accordingly been retired from most institutional order sets.

What replaced it

Nothing exotic replaced the Marik cocktail—the field returned to evidence-based sepsis fundamentals. What actually moves outcomes in sepsis is early recognition, prompt broad-spectrum antibiotics, source control, balanced-crystalloid fluid resuscitation guided by perfusion, and vasopressors (norepinephrine first-line) titrated to a mean arterial pressure target, with corticosteroids reserved for shock that remains vasopressor-dependent. Hydrocortisone has its own evidence base in septic shock independent of vitamin C, which is part of why the HAT trials compared the combination against hydrocortisone alone. The lesson of the episode was not that a better cocktail is waiting to be found, but that supportive micronutrient "boosts" are no substitute for the unglamorous bundle that the Surviving Sepsis Campaign already recommends.

Why the idea was plausible—and why that was not enough

The original rationale was not unreasonable: critically ill septic patients often have low plasma vitamin C, the vitamin is an antioxidant and a cofactor for endogenous catecholamine and cortisol synthesis, and in the laboratory it can blunt some inflammatory and endothelial-injury pathways. That mechanistic story, combined with a dramatic before-after mortality difference, was enough to drive rapid adoption. But mechanistic plausibility and a striking uncontrolled result are exactly the conditions under which medicine is most often fooled—historical controls differ from treated patients in countless unmeasured ways, and only randomization breaks that bias. When randomization was applied, the effect vanished, and in the largest trial it reversed.

Why high-dose IV vitamin C is not benign

Vitamin C is metabolized in part to oxalate, and high intravenous doses produce an oxalate load that, in patients with renal impairment, can precipitate calcium oxalate crystals in the renal tubules. Acute oxalate nephropathy from high-dose IV vitamin C has been described, particularly in people with chronic kidney disease or pre-existing oxalate burden. In addition, high circulating vitamin C interferes with many point-of-care glucometers, producing falsely elevated glucose readings that can prompt inappropriate insulin dosing in the ICU—a practical hazard independent of any direct toxicity.

Where IV vitamin C still has a defined role

The collapse of the sepsis claim does not make intravenous vitamin C useless. It remains the appropriate treatment for severe scurvy when oral repletion is not feasible, and it is studied as a supportive, quality-of-life-oriented adjunct in some oncology settings, where the goal is symptom burden rather than tumor control and the evidence is still preliminary. Burn resuscitation has explored high-dose vitamin C with mixed, non-definitive results. Outside these specific, supervised contexts, megadose intravenous vitamin C should not be used—and it is certainly not something to seek out at an infusion clinic on the strength of the discredited sepsis story.

Sources

1. Marik PE, Khangoora V, Rivera R, et al. "Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study." Chest, 2017;151(6):1229–1238. PMID 27940189.
2. Fujii T, Luethi N, Young PJ, et al. "Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial." JAMA, 2020;323(5):423–431. PMID 31950979.
3. Fowler AA, Truwit JD, Hite RD, et al. "Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial." JAMA, 2019;322(13):1261–1270. PMID 31573637.
4. Moskowitz A, Huang DT, Hou PC, et al. "Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial." JAMA, 2020;324(7):642–650. PMID 32809003.
5. Lamontagne F, Masse MH, Menard J, et al. "Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit (LOVIT)." N Engl J Med, 2022;386(25):2387–2398. PMID 35704292.
6. Wen C, Li Y, Hu Q, et al. "IV Vitamin C in Sepsis: A Latest Systematic Review and Meta-Analysis." Int J Clin Pract, 2023;2023:6733465. PMID 36743822.
7. Zeng Y, Liu Z, Xu F, Tang Z. "Intravenous high-dose vitamin C monotherapy for sepsis and septic shock: A meta-analysis of randomized controlled trials." Medicine (Baltimore), 2023;102(42):e35648. PMID 37861551.